Overview

Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat pain, addiction and psychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix's lead product candidate, TNX-102 SL, is in Phase 3 development as a bedtime treatment for fibromyalgia. Tonix is also developing TNX-102 SL as a bedtime treatment for agitation in Alzheimer's disease. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of major depressive disorder and PTSD, and is designed for daytime dosing. Tonix's lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.

Seth Lederman, MD

Co-Founder, CEO & Chairman

Seth Lederman is a physician, scientist and founder and executive officer of innovative biopharmaceuticals companies. Prior to founding Tonix, among the companies Dr. Lederman founded was Targent Pharmaceuticals, which developed late-stage…

View Full Bio

Gregory Sullivan, MD

Chief Medical Officer

Dr. Sullivan is a physician and scientist. Dr. Sullivan joined Tonix Pharmaceuticals from Columbia University (CU), where he was most recently an Assistant Professor of Psychiatry in the Department of Psychiatry at Columbia University…

View Full Bio

Bradley Saenger, CPA

Chief Financial Officer

Bradley Saenger joined Tonix in May 2014, as Director of Accounting (May 2014 – December 2015) and was promoted to VP of Accounting (January 2016 – February 2016) and to Chief Financial Officer (February 2016). Mr. Saenger has…

View Full Bio

Jessica Edgar Morris

Chief Operating Officer

Jessica Edgar Morris joined Tonix Pharmaceuticals as Senior Vice President of Finance in September 2013. Ms. Morris served as Acting Chief Financial Officer from January 2016 to February 2016 and was subsequently appointed Executive Vice…

View Full Bio

Herbert Harris, M.D., Ph.D.

Executive Vice President, Translational Medicine

Dr. Harris earned his M.D. and Ph.D. degrees from the University of Pittsburgh. Dr. Harris’ Ph.D. work in immunology involved the regulation of cell surface expression and turnover of Class I MHC antigens, which are the targets of CD8 T…

View Full Bio

Seth Lederman, MD

Co-Founder, CEO & Chairman

View Full Bio

Richard H. Bagger

Director

Rich Bagger is a Partner and Executive Director of Christie 55 Solutions, LLC, a New Jersey based consulting firm that provides strategic counsel and consulting services to assist clients with business strategies and opportunities, and…

View Full Bio

Margaret Smith Bell

Director

Margaret Smith Bell was a Vice President at Standard Life Investments where she was a portfolio manager and health care equity analyst. Previously, Ms. Bell was a Managing Director at Putnam Investments, and served as a senior health care…

View Full Bio

Daniel Goodman, MD

Director

Dr. Goodman is a psychiatrist and scientist entrepreneur. Dr. Goodman was co-founder and CEO of PsychoGenics, a leading preclinical neuropharmacology company that combines its in vivo behavioral expertise with robotics, computer vision,…

View Full Bio

Brigadier General David Grange (ret)

Director

Brigadier General (BD) David Grange (U.S. Army retired) has been President and founder of Osprey Global Solutions, LLC (“OGS”), a Service Disabled Veterans Organization, since 2011. BG Grange was Chief Executive Officer of…

View Full Bio

Adeoye Olukotun, MD

Director

Dr. Olukotun is the Chief Executive Officer of CR Strategies, LLC, which consults on clinical trial design and FDA strategy for pharmaceutical product development. He is the former Chief Executive Officer of EpiGen Pharmaceuticals, Inc.…

View Full Bio

James Treco

Director

Mr. Treco is a Managing Partner at First Chicago Advisors, Inc., a boutique financial advisory firm where he advises executives and boards of directors of a wide range of companies, from global, large-cap companies to emerging companies.…

View Full Bio

Investor Relations
TONIX Pharmaceuticals
investor.relations@tonixpharma.com

Transfer Agent
vStock Transfer
77 Spruce Street
Suite 201
Cedarhurst, NY 11516
T: 212-828-8436
www.vstocktransfer.com

Investors

Latest News

Tonix Pharmaceuticals Plans Massachusetts R&D Facility to Accelerate Clinical Development of Vaccines and Protein-Based Therapeutics

Latest Financial Results

Latest Annual Report

10-K

Stock Information

Symbol

Price

Change

MKT Cap

Volume

52 week Low/High

Day Low/High

Company Overview

Officers & Directors

Seth Lederman, MD

Gregory Sullivan, MD

Bradley Saenger, CPA

Jessica Edgar Morris

Herbert Harris, M.D., Ph.D.

Seth Lederman, MD

Richard H. Bagger

Margaret Smith Bell

Daniel Goodman, MD

Brigadier General David Grange (ret)

Adeoye Olukotun, MD

James Treco

IR Contact Information

Investor Relations

Investors

Latest News

Tonix Pharmaceuticals Plans Massachusetts R&D Facility to Accelerate Clinical Development of Vaccines and Protein-Based Therapeutics

Sign up for email alerts

Latest Financial Results

Latest Annual Report

10-K

Stock Information

Symbol

Price

Change

MKT Cap

Volume

52 week Low/High

Day Low/High

Company Overview

Officers & Directors

Seth Lederman, MD

Gregory Sullivan, MD

Bradley Saenger, CPA

Jessica Edgar Morris

Herbert Harris, M.D., Ph.D.

Seth Lederman, MD

Richard H. Bagger

Margaret Smith Bell

Daniel Goodman, MD

Brigadier General David Grange (ret)

Adeoye Olukotun, MD

James Treco

IR Contact Information